To raise capital, biotechs need specific clinical data. Raj Devraj specifies the three essential components investors look for: 1) confirmation of good drug exposure in humans, 2) a favorable early safety profile, and 3) biomarker data that provides proof of the drug's biological mechanism. Lacking any of these makes fundraising significantly harder.

Investors without a scientific background can de-risk biotech portfolios by avoiding early-stage "science projects" (Phase 1-2). Instead, they should focus on companies that have completed Phase 3 trials. This strategy shifts the primary risk from unpredictable scientific development to more analyzable commercial execution.

In an scientifically inscrutable sector, the percentage of a company owned by dedicated biotech funds serves as a reliable proxy for quality. A complete lack of specialist ownership is a major red flag, suggesting the company is likely marketed to uninformed investors and may have poor science.

The life sciences investor base is highly technical, demanding concrete data and a clear path to profitability. This rigor acts as a natural barrier to the kind of narrative-driven, AI-fueled hype seen in other sectors, delaying froth until fundamental catalysts are proven.

Biotech firms are beginning to selectively disclose clinical data, citing the need to protect R&D from fast-following competitors, particularly from China. This forces investors into a difficult position: either trust management without full transparency or discount the company's value due to the opacity.

It's not enough to believe a drug trial will be positive. To generate true alpha, an investor must also have a well-researched, specific explanation for what misconceptions or concerns are causing other market participants to misprice the asset.

Many PE firms use backward-looking commercial due diligence, which is superficial and fails to assess a target's true growth potential. A more effective approach is go-to-market focused due diligence that evaluates the scalability of the future revenue engine, not just past performance.

Market dynamics, like investor fixation on AI or predatory short-selling, pose a greater risk to biotech firms than clinical trial results. A company can have a breakthrough drug but still fail if its stock—its funding currency—is ignored or attacked by Wall Street.

When seeking partnerships, biotechs should structure their narrative around three core questions pharma asks: What is the modality? How does the mechanism work? And most importantly, why is this the best differentiated approach to solve a specific clinical challenge and fit into the competitive landscape?